$PLRX News
Last published 2d ago
- 2d agoPLRXPliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of CancerGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced the presentation of preclinical proof-of-concept data and new clinical biomarker analyses related to PLN-101095 at the 41 st Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
- 2d agoPLRXPliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of CancerGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), today announced the presentation of preclinical proof-of-concept data and new clinical biomarker analyses related
- 1w agoPLRXPliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of CancerGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics,
- 3w agoPLRXPliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)GlobeNewswireRecognized leader in RNAi drug discovery with track record of advancing novel delivery platforms and therapeutics to drive Company’s integrin-mediated delivery platform SOUTH SAN FRANCISCO, Calif., Oct. 20, 2026
- 3w agoPLRXPliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026GlobeNewswireFeatures FORTIFY, the ongoing Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics,
- 2mo agoPLRXPliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid TumorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for
- 4mo agoPLRXPliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of DirectorsGlobeNewswireAppointments bring global oncology drug development experience and deepen Board’s operational and regulatory expertise SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc.
- 5mo agoPLRXPliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual MeetingGlobeNewswireHighlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095��enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc.
- 6mo agoPLRXAtisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the BoardPR NewswireAtisama Therapeutics (formerly Rage Bio) ("Atisama" or the "Company"), an Australian clinical-stage biotechnology company developing novel...
- 6mo agoPLRXPliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial ResultsGlobeNewswireFirst participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confirmed responses in
- 6mo agoPLRXPliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics,
- 6mo agoPLRXPliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid TumorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (NASDAQ:PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical
- 6mo agoPLRXPliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual MeetingGlobeNewswireConfirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months Data highlighted in oral presentation at AACR's Clinical Trials Mini
- 8mo agoPLRXPliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics,
- 11mo agoPLRXPliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid TumorsGlobeNewswireOne complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatment of 15 months
- 11mo agoPLRXPliant Therapeutics to Participate in the Piper Sandler Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today
- 1y agoPLRXPliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial ResultsGlobeNewswireOncology program advancing with data expected in the fourth quarter 2025 BEACON-IPF close out activities to be completed in the fourth quarter 2025 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) --
- 1y agoPLRXPliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsGlobeNewswireBEACON-IPF close out activities continue Previously announced workforce and operational realignment largely complete Phase 1 oncology trial on track to deliver additional data by the end of the year SOUTH SAN
- 1y agoPLRXPliant Therapeutics Provides Update on BEACON-IPFGlobeNewswireBexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025
- 1y agoPLRXPliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical data this week as
- 1y agoPLRXPliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsGlobeNewswireActivities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash runway to support
- 1y agoPLRXPliant Therapeutics Announces Strategic Realignment of Workforce and OperationsGlobeNewswire- Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials - Pliant will reduce its current workforce by approximately 45% - Closing activities for BEACON-IPF trial
- 1y agoPLRXPliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that the Company will present three scientific posters at the upcoming 2025 American Thoracic
- 1y agoPLRXPliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid TumorsGlobeNewswireAntitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across multiple tumor types PLN-101095 was generally well tolerated across all doses SOUTH SAN FRANCISCO,
- 1y agoPLRXSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Pliant Therapeutics, Inc. ("Pliant" or the...
- 1y agoPLRXPliant Therapeutics Adopts Limited Duration Stockholder Rights AgreementGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights
- 1y agoPLRXPliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial ResultsGlobeNewswireDiscontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage
- 1y agoPLRXPliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary FibrosisGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that following a prespecified data review and recommendation by the trial's independent Data
- 1y agoPLRXPliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary FibrosisGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that, per the charter of the trial's independent Data Safety Monitoring Board (DSMB), the Company
- 1y agoPLRXPliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary FibrosisGlobeNewswireFollowing DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current patients while data is reviewed SOUTH SAN FRANCISCO, Calif., Feb. 07,
- 1y agoPLRXPliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), today announced that on January 21, 2025, it granted stock options to purchase an aggregate of 275,000 shares of
- 1y agoPLRXPliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical OfficerGlobeNewswireDr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc.
- 1y agoPLRXPliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present at
- 1y agoPLRXPliant Therapeutics to Participate in Upcoming Investor EventsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the
- 1y agoPLRXPliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024GlobeNewswireINTEGRIS-PSC featured in an oral late breaker presentation SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the
- 2y agoPLRXPliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsGlobeNewswireBEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc.
- 2y agoPLRXPliant Therapeutics to Participate in the Stifel Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), today announced that Keith Cummings, M.D., Chief Financial Officer, and Greg Cosgrove, M.D. FCCP, will participate in a
- 2y agoPLRXPliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024GlobeNewswireINTEGRIS-PSC to be featured in an oral presentation on Monday, November 18 SOUTH SAN FRANCISCO, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and
- 2y agoPLRXPliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical AffairsGlobeNewswireFormer Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage
- 2y agoPLRXPliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), today announced that on September 30, 2024 it granted stock options to purchase an aggregate of 120,000 shares of
- 2y agoALGSHAENVOPLRX+2Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical OfficerGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies
- 2y agoPLRXPliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024GlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the
- 2y agoPLRXPliant Therapeutics to Participate in Upcoming Investor EventsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the
- 2y agoKRROMRKRPLRXKorro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and
- 2y agoPLRXPliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024GlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the
- 2y agoPLRXPliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsGlobeNewswirePositive data from a 12-week Phase 2a PET imaging trial demonstrated reduced total lung collagen, improved FVC and reduced cough severity in IPF patients treated with bexotegrast Positive long-term data from
- 2y agoPLRXPliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that Keith Cummings, M.D., Chief Financial Officer, and Éric Lefebvre, M.D., Chief Medical Officer,
- 2y agoPLRXPliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple MeasuresGlobeNewswireBexotegrast at 320 mg was well tolerated up to 40 weeks of treatment with no treatment-related severe or serious adverse events 320 mg cohort demonstrated improvement in liver stiffness by transient
- 2y agoPLRXPliant Therapeutics Announces Appointment of Steve Krognes to Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of
- 2y agoPLRXPliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), today announced that on June 10, 2024, it granted stock options to purchase an aggregate of 120,000 shares of